Effect of Cequa Treatment on Accuracy of Pre-operative Biometry & Higher Order Aberrations in Dry Eye Patients Undergoing Cataract Surgery

Inclusion Criteria: * Patients with planned cataract surgery, * The presence of central or inferior corneal fluorescein staining defined by the Oxford Scale * Reduced tear break up time (TBUT) ≤ 10 seconds. * Able to comprehend and sign a statement of informed consent. * Willing and able to complete all required postoperative visits. Exclusion Criteria: * Ocular surgery (e.g., intraocular, oculoplastic, corneal or refractive surgical procedure) performed within the last 3 months or at any time that in the investigator's clinical judgment if it would interfere with the outcome measures of this study. * Clinically significant ocular trauma. * Active ocular Herpes simplex or Herpes Zoster infection * Ocular inflammation (uveitis, iritis, scleritis, episcleritis, keratitis, conjunctivitis) at the discretion of the investigator. * Ocular infection (e.g., viral, bacterial, mycobacterial, protozoan or fungal infection or the cornea, conjunctiva, lacrimal gland, lacrimal sac or eyelids including hordeolum/stye). * Active, systemic or local disease condition that causes clinically significant ocular surface irritation such that it could interfere with the study findings. * Moderate to severe (Grade 2-4) allergic, vernal or giant papillary conjunctivitis. * Severe (Grade 3 or 4) inflammation of the eyelid (e.g., blepharochalasis, staphylococcal blepharitis or seborrheic blepharitis) * Eyelid abnormalities that significantly affect the lid function (e.g., entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis). * Ocular surface abnormality that may compromise the corneal integrity (e.g., prior chemical burn, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal fluorescein staining, map dot fingerprint dystrophy, or the effect of any other ophthalmic medication that might in the opinion of the investigator compromise the ocular surface integrity). * Participation in this trial in the same patient's fellow eye * Patients who are under age 18, pregnant or breastfeeding, or who may become pregnant during participation in the study.